News Releases
NervGen Pharma Announces First Subject Dosed in Landmark Phase 1b/2a Clinical Trial for NVG-291 in Spinal Cord Injury
Chronic spinal cord injury cohort results expected in mid-2024 Subacute spinal cord injury cohort results expected in late 2024/early 2025 Vancouver, Canada, September 25,
NervGen Pharma to Present at 2023 International Spinal Research Trust Network Meeting
Vancouver, Canada, September 11, 2023 – NervGen Pharma Corp. (TSX-V: NGEN; OTCQX: NGENF) (“NervGen” or the “Company”), a clinical stage biotech company dedicated to developing
NervGen Pharma to Present on Its Drug Candidate NVG-291 and Spinal Cord Injury at the H.C. Wainwright 25th Annual Global Investment Conference
Vancouver, Canada. September 5, 2023 – NervGen Pharma Corp. (TSX-V: NGEN; OTCQX: NGENF), a clinical stage biotech company dedicated to developing innovative solutions for the treatment of
NervGen Pharma to Present on its Drug Candidate NVG-291 and Spinal Cord Injury at Investor Conference
Vancouver, Canada. August 22, 2023 – NervGen Pharma Corp. (TSX-V: NGEN; OTCQX: NGENF), a clinical stage biotech company dedicated to developing innovative solutions for the
NervGen Pharma Reports Q2 2023 Financial Results and Operational Updates
Landmark Phase 1a/2b clinical trial of NVG-291 proceeds with recruitment of individuals with spinal cord injury; results expected in mid-2024 Seasoned life sciences executive, Mike
NervGen Pharma to Proceed with Landmark Phase 1b/2a Clinical Trial for NVG-291 in Spinal Cord Injury Having Completed FDA Review and Received IRB Approval
Recruitment of individuals with spinal cord injury (SCI) initiated at Shirley Ryan AbilityLab in Chicago Chronic SCI cohort results expected in mid-2024 and subacute SCI
NervGen Pharma to Receive More Than US$3 Million from Wings for Life to Support Upcoming Clinical Study in Spinal Cord Injury
Vancouver, Canada. June 27, 2023 – NervGen Pharma Corp. (TSX-V: NGEN; OTCQX: NGENF) (“NervGen” or the “Company”), a clinical stage biotech company dedicated to developing
NervGen Pharma to Present at Upcoming Investor Conferences
Vancouver, Canada. June 20, 2023 – NervGen Pharma Corp. (TSX-V: NGEN; OTCQX: NGENF) (“NervGen” or the “Company”), a clinical stage biotech company dedicated to developing
NervGen Pharma Extends the Expiry Date of Certain Stock Options
Vancouver, Canada. June 2, 2023 – NervGen Pharma Corp. (TSX-V: NGEN) (OTCQX: NGENF) (“NervGen” or the “Company”), a clinical stage biotech company dedicated to developing
NervGen Pharma Grants Stock Options
Vancouver, Canada. May 23, 2023 – NervGen Pharma Corp. (TSX-V: NGEN) (OTCQX: NGENF) (“NervGen” or the “Company”), a clinical stage biotech company dedicated to developing
NervGen Pharma Announces Results of Annual General Meeting of Shareholders
All resolutions submitted for approval were passed by shareholders Vancouver, Canada, May 18, 2023 — NervGen Pharma Corp. (TSX-V: NGEN) (OTCQX: NGENF), a clinical stage
NervGen Pharma Reports Q1 2023 Results and Provides Operational Update Including Clinical Trials of Proprietary NVG-291
Phase 1 clinical trial dosing completed Phase 1b/2a clinical trial of NVG-291 in individuals with chronic and subacute spinal cord injuries expected to commence in
NervGen Pharma Presenting Phase 1b/2a Study Design at American Spinal Injury Association 50th Annual Scientific Meeting
Phase 1b/2a trial expected to commence in Q3 2023 First readout anticipated in 2024 Vancouver, Canada. April 13, 2023 – NervGen Pharma Corp. (TSX-V: NGEN) (OTCQX:
NervGen Pharma Appoints Michael Kelly as President & Chief Executive Officer
Vancouver, Canada. April 10, 2023 – NervGen Pharma Corp. (TSX-V: NGEN; OTCQX: NGENF) (“NervGen” or the “Company”), a clinical stage biotech company dedicated to developing
NervGen Pharma Reports 2022 Year End Results and Provides Operational Update Including Plans to Initiate Phase 1b/2a Clinical Trial of Proprietary NVG-291 in Q3 2023
Equity proceeds of CA$22M+ raised during 2022 fiscal year Phase 1 clinical trial dosing of proprietary compound, NVG-291, is complete and data analysis is ongoing